FluoSphera

Executive Summary

FluoSphera is a Swiss biotechnology company pioneering a first-of-its-kind technology platform that analyzes and predicts systemic inter-organ communications mediated by blood. Founded in 2019, the company addresses a critical gap in drug discovery: understanding how drugs affect the body as an integrated system, rather than isolated targets. By modeling the complex signaling between organs via blood, FluoSphera aims to improve the prediction of clinical outcomes and reduce late-stage drug failures. The platform has potential applications across cell therapy and drug delivery, offering insights into off-target effects, efficacy, and toxicity. While still in early stages, FluoSphera's approach could transform preclinical drug development by providing a more holistic view of drug action.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026Proof-of-Concept Publication in Peer-Reviewed Journal70% success
• H1 2027Strategic Partnership with Major Pharma Company40% success